Background: Macrophage activation may contribute to accelerated atherosclerosis in HIV-infected persons. We hypothesized that HCV coinfection increases macrophage activation and cardiovascular disease (CVD) risk, and that successful HCV treatment in coinfected persons reduces CVD risk through reduction in macrophage activation. Methodology: Of 54 coinfected subjects who received up to 72 weeks of pegylated interferon/ribavirin (PEG/RBV), 27 with and 27 without sustained virologic response (SVR, HCV RNA<60 IU/mL 24 weeks after end of treatment [EOT]) matched by race/ethnicity and sex, stored plasma before treatment and 24 weeks after EOT were tested for soluble CD14 (sCD14) and CD163 (sCD163). Baseline characteristics and biomarkers were compared between SVRs and non-SVRs by Fisher’s exact and Wilcoxon tests and associations between biomarkers and baseline variables by simple regression. Changes in each biomarker were examined within and between groups by t-test and regression models adjusting for race/ethnicity, sex, and with backward selection of baseline variables significant at 0.10 level (HCV RNA, fibrosis stage, HCV treatment history, AST and ALT level) (Model 1), and further controlling for change in ALT (Model 2) and PEG/RBV duration (Model 3). Results: Of 54 subjects, 30 white, 24 black, and 44 male, 78% had HIV-1 RNA<50 copies/mL. Median [Q1, Q3] CD4 was 544 [370, 734] cells/μL. 3 SVR and 4 non-SVR subjects had baseline CVD; none had a CVD event on study. The Table describes baseline and change in markers. Baseline sCD163 was associated with fibrosis stage (P<0.001) and baseline ALT (P<0.001). Controlling for fibrosis, there was no difference in baseline sCD163 by SVR status (P=0.094). In Model 1 adjusting for race/ethnicity, sex and baseline AST after backward selection, SVR was associated with decrease in log10 sCD163 (p=0.042), but not after further adjusting for change in ALT (Model 2, P=0.096, change in ALT P=0.002) or PEG/RBV duration (Model 3, P=0.071, PEG/RBV P=0.052). Conclusions: SVR was associated with decrease in plasma sCD163 but not sCD14 levels. Adjustment for change in ALT attenuated the association between SVR and sCD163, suggesting hepatic inflammation may mediate this association. HCV treatment may reduce hepatically-driven macrophage activation, with greater sensitivity of sCD163 as compared to sCD14 to hepatic inflammation. Degree of liver disease must be considered in the interpretation of macrophage activation markers in HIV-infected persons.